DoD's $380M COVID-19 testing contract awarded to Orasure Technologies Inc. for pharmaceutical preparations

Contract Overview

Contract Amount: $388,440,000 ($388.4M)

Contractor: Orasure Technologies Inc

Awarding Agency: Department of Defense

Start Date: 2021-10-20

End Date: 2022-10-06

Contract Duration: 351 days

Daily Burn Rate: $1.1M/day

Competition Type: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8508632127!INTELISWAB COVID-19 ST OTC U

Place of Performance

Location: BETHLEHEM, NORTHAMPTON County, PENNSYLVANIA, 18015

State: Pennsylvania Government Spending

Plain-Language Summary

Department of Defense obligated $388.4 million to ORASURE TECHNOLOGIES INC for work described as: 8508632127!INTELISWAB COVID-19 ST OTC U Key points: 1. Contract value of $380M represents significant investment in pandemic preparedness. 2. Sole-source award raises questions about competition and potential for cost savings. 3. Limited competition may indicate a specialized need or a lack of market alternatives. 4. Contract duration of 351 days suggests a focused, short-term operational requirement. 5. The pharmaceutical preparation manufacturing sector is critical for public health responses. 6. Awarded by the Defense Logistics Agency, highlighting military support for civilian health needs.

Value Assessment

Rating: questionable

The contract's value of $380 million for COVID-19 testing supplies warrants scrutiny. Without comparable contract data for similar large-scale, sole-source procurements of this specific type of pharmaceutical preparation, it is difficult to benchmark the value for money. The pricing structure (Firm Fixed Price) provides cost certainty but does not inherently guarantee optimal value. Further analysis would require understanding the unit costs and comparing them to market rates for similar testing kits or components.

Cost Per Unit: N/A

Competition Analysis

Competition Level: limited

This contract was awarded under 'FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES,' which is a form of limited competition. This suggests that while an initial attempt at broad competition may have occurred, only specific sources were ultimately considered or qualified. The limited number of bidders, or potentially a single bidder in practice, can lead to less aggressive pricing and potentially higher costs for the government compared to a fully open and competitive process.

Taxpayer Impact: Limited competition can result in taxpayers paying a premium, as the government may not benefit from the most competitive pricing available in the market. This can divert funds that could otherwise be used for other essential services or programs.

Public Impact

The primary beneficiaries are military personnel and potentially civilian populations served by the Department of Defense's health initiatives, ensuring access to COVID-19 testing. The contract delivers essential pharmaceutical preparations for COVID-19 testing, crucial for disease surveillance and control. Geographic impact is likely nationwide, supporting DoD facilities and operations across various locations. Workforce implications may include increased demand for manufacturing and logistics personnel within Orasure Technologies Inc. and its supply chain.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Limited competition raises concerns about potential overpayment and lack of cost-effectiveness.
The sole-source nature of the award warrants investigation into the justification for excluding other potential bidders.
Lack of transparency in the bidding process could obscure potential risks or inefficiencies.
Dependence on a single contractor for critical supplies can create supply chain vulnerabilities.

Positive Signals

The award addresses a critical public health need during a pandemic, ensuring the availability of essential testing supplies.
A firm fixed-price contract provides cost certainty for the government, mitigating budget risks.
The contractor, Orasure Technologies Inc., is likely experienced in producing such medical supplies, suggesting a degree of reliability.

Sector Analysis

The pharmaceutical preparation manufacturing sector is a vital component of the healthcare and life sciences industry, particularly crucial during public health emergencies. This contract falls within the broader scope of medical supplies and diagnostics. Comparable spending benchmarks are difficult to establish without more specific details on the exact nature of the 'pharmaceutical preparations' and the scale of the testing kits involved. However, government spending on pandemic-related supplies has seen a significant increase since 2020.

Small Business Impact

The data indicates that this contract was not set aside for small businesses (ss: false, sb: false). Therefore, there are no direct subcontracting implications or specific benefits for the small business ecosystem stemming from this particular award. The focus appears to be on fulfilling a large-scale requirement with established industry players.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Defense and the Defense Logistics Agency. Accountability measures are typically embedded within the contract terms, including performance standards and delivery schedules. Transparency is assessed through the availability of contract award data. Inspector General jurisdiction would apply if any fraud, waste, or abuse is suspected.

Related Government Programs

COVID-19 Testing Supplies Procurement
Department of Defense Medical Materiel
Pharmaceutical Manufacturing Contracts
Public Health Emergency Response
Defense Logistics Agency Contracts

Risk Flags

Limited Competition
Potential for Overpricing
Supply Chain Dependency
Lack of Transparency in Source Selection

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $388.4 million to ORASURE TECHNOLOGIES INC. 8508632127!INTELISWAB COVID-19 ST OTC U

Who is the contractor on this award?

The obligated recipient is ORASURE TECHNOLOGIES INC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $388.4 million.

What is the period of performance?

Start: 2021-10-20. End: 2022-10-06.

What is the specific nature of the 'Pharmaceutical Preparation Manufacturing' for COVID-19 testing, and how does it differ from standard testing kits?

The term 'Pharmaceutical Preparation Manufacturing' in this context likely refers to the chemical reagents, enzymes, or other biological components that are essential for the functioning of COVID-19 diagnostic tests, rather than the complete testing kits themselves. These preparations are the active ingredients that enable the test to detect the presence of the virus. This could include reagents for PCR tests, components for antigen tests, or other specialized chemical mixtures. The distinction is important because manufacturing these specific chemical or biological components may require specialized facilities and expertise, potentially limiting the number of qualified suppliers and justifying a less open competition.

What was the justification for excluding other sources in this 'Full and Open Competition After Exclusion of Sources' award?

The justification for excluding other sources under this contract type typically stems from specific technical requirements, unique capabilities, or urgent needs that only a limited number of contractors can meet. For pharmaceutical preparations related to COVID-19 testing, this could involve proprietary manufacturing processes, specific certifications for handling sensitive biological materials, or the ability to scale production rapidly to meet a large government demand. The contracting agency would have had to document why other potential sources were not capable of fulfilling the requirement, often involving extensive market research and technical evaluations.

How does the $380 million contract value compare to historical spending on similar pharmaceutical preparations for diagnostic purposes?

Comparing the $380 million contract value to historical spending on similar pharmaceutical preparations for diagnostic purposes is challenging without more granular data on the specific components procured and their unit costs. However, it is widely understood that spending on COVID-19 related medical supplies, including diagnostic components, surged dramatically during the pandemic. Pre-pandemic spending on such specialized reagents would likely have been significantly lower. The scale of this award reflects the unprecedented demand and urgency driven by the global health crisis.

What are the potential risks associated with a limited competition award of this magnitude for critical health supplies?

A limited competition award of this magnitude for critical health supplies carries several potential risks. Firstly, there is the risk of reduced price competition, which could lead to the government paying a higher price than if the contract were fully open. Secondly, it can create a dependency on a single or limited number of suppliers, making the supply chain vulnerable to disruptions. If the awarded contractor faces production issues, quality control problems, or financial instability, it could significantly impact the availability of essential testing materials. Lastly, the lack of broad competition might obscure potential inefficiencies or less innovative solutions that could have emerged from a more diverse bidder pool.

What performance metrics or quality control measures are likely in place for this contract to ensure the effectiveness of the pharmaceutical preparations?

For a contract of this nature, especially involving pharmaceutical preparations for diagnostic use, stringent performance metrics and quality control measures are expected. These would typically include adherence to Good Manufacturing Practices (GMP), specific purity and potency standards for the reagents, and rigorous testing protocols for each batch produced. The contract likely specifies acceptance criteria for delivered materials, potentially including independent laboratory verification. Performance would also be monitored through on-time delivery schedules and compliance with all regulatory requirements set forth by agencies like the FDA, even if indirectly through the DoD's quality assurance processes.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: INSTRUMENTS AND LABORATORY EQPT

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION AFTER EXCLUSION OF SOURCES

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 220 E 1ST ST, BETHLEHEM, PA, 18015

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $388,440,000

Exercised Options: $388,440,000

Current Obligation: $388,440,000

Actual Outlays: $41,490,890

Contract Characteristics

Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE21D0049

IDV Type: IDC

Timeline